{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-032353","form_type":"8-K/A","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2022-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.323848+00:00","generated_at":"2026-06-21T19:04:24.363897+00:00","sec_items":["2.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Sanara MedTech amends Q3 2022 8-K to correct CellerateRX facility count from 1,593 to 1,714","bullets":["Original filing reported CellerateRX approved in 1,593 facilities as of Sep 30, 2022.","Acquisition of Scendia Biologics added 121 facilities, bringing corrected total to 1,714.","Amendment only revises this specific number; all other disclosures remain unchanged.","No change to financial results or any other operational metrics."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-032353","json":"https://secwatch.observer/filing/0001493152-22-032353.json","markdown":"https://secwatch.observer/filing/0001493152-22-032353.md","text":"https://secwatch.observer/filing/0001493152-22-032353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000149315222032353/0001493152-22-032353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000149315222032353/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:04:24.363897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2a402496bf87213ee5c15d47858e999a2d47553","claim":"Sanara MedTech Inc. reported financial results for quarter ended September 30, 2022.","evidence_excerpt":"On November 14, 2022, the Company furnished (i) a press release announcing its financial results for the quarter ended September 30, 2022 (the “Press Release”)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/714256/000149315222032353/0001493152-22-032353-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}